Ken Fisher Sage Therapeutics, Inc. Transaction History

Fisher Asset Management, LLC

$229 Billion
Q2 2024

A detailed history of Ken Fisher (Fisher Asset Management, LLC) transactions in Sage Therapeutics, Inc. stock. As of the latest transaction made, Fisher Asset Management, LLC holds 436,421 shares of SAGE stock, worth $3.15 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

436,421

Previous 432,469 0.91%

Holding current value

$3.15 Million

Previous $8.1 Million 41.52%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$10.58 - $17.9 $41,812 - $70,740	3,952 Added 0.91%	436,421 $4.74 Million
Q1 2024 May 09, 2024	BUY	$18.62 - $26.95 $10,129 - $14,660	544 Added 0.13%	432,469 $8.1 Million
Q4 2023 Mar 05, 2024	BUY	$17.1 - $22.26 $6,942 - $9,037	406 Added 0.09%	431,925 $9.36 Million
Q4 2023 Feb 06, 2024	BUY	$17.1 - $22.26 $545,490 - $710,094	31,900 Added 7.98%	431,519 $9.35 Million
Q3 2023 Nov 13, 2023	SELL	$16.75 - $48.98 $528,077 - $1.54 Million	-31,527 Reduced 7.31%	399,619 $8.22 Million
Q2 2023 Dec 12, 2023	BUY	$40.65 - $59.54 $1.28 Million - $1.88 Million	31,527 Added 7.89%	431,146 $20.3 Million
Q2 2023 Aug 08, 2023	BUY	$40.65 - $59.54 $399,304 - $584,861	9,823 Added 2.33%	431,146 $20.3 Million
Q1 2023 Dec 12, 2023	BUY	$37.27 - $46.57 $793,776 - $991,847	21,298 Added 5.33%	420,917 $17.7 Million
Q1 2023 May 01, 2023	SELL	$37.27 - $46.57 $643,019 - $803,472	-17,253 Reduced 3.93%	421,323 $17.7 Million
Q4 2022 Feb 03, 2023	SELL	$32.2 - $43.61 $200,863 - $272,039	-6,238 Reduced 1.4%	438,576 $16.7 Million
Q3 2022 Nov 08, 2022	BUY	$32.28 - $43.27 $14.4 Million - $19.2 Million	444,814 New	444,814 $17.4 Million

Others Institutions Holding SAGE

# of Institutions

217

Shares Held

48.2M

Call Options Held

854K

Put Options Held

195K

View Full List

About Sage Therapeutics, Inc.

Ticker SAGE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,422,300
Market Cap $428M
Description
Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines to treat central nervous system disorders. Its lead product candidate is ZULRESSO, an intravenous formulation of brexanolone for the treatment of postpartum depression (PPD) in adults. The company's product pipeline also includes zuranolone, a neuroactive...

More about SAGE

Track Ken Fisher's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Fisher Asset Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Fisher Asset Management, LLC and Ken Fisher with notifications on news.

Account